Explore groundbreaking studies, clinical trial updates, and emerging technologies shaping the future of cancer treatment.
Exploring the potential of BGB-11417 (sonrotoclax) as a next-generation BCL2 inhibitor for treating advanced blood cancers with promising clinical trial results.